# Pablo Cironi

> Pablo Cironi is a seed investor at Criteria Bio Ventures backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Criteria Bio Ventures](https://shizune.co/investors/profile/criteria-bio-ventures)
- Location: Barcelona, Spain
- Total investments: 5
- Last investment: Oct 2025
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/cironi/

Pablo Cironi is a seed investor at Criteria Bio Ventures in Barcelona focused on Biotechnology and Health Care. Pablo Cironi is based out of Barcelona, Spain and is the Managing Director of Criteria Bio Ventures and also the Chairman of the Board of Adaptam Therapeutics. Pablo previously worked at Aelix Therapeutics as a Board of Directors. Pablo Cironi attended the University of Buenos Aires.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 2 | 40% |
| Medical | 1 | 20% |
| Genetics | 1 | 20% |
| Life Science | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 20% |
| Pre-Seed | 1 | 20% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 2 | 40% |
| France | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adaptam Therapeutics | Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies | $3.5M | Pre-Seed | Oct 27, 2025 |  |
| Tolerance Bio | Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus. | $20.2M | Seed | Oct 15, 2024 |  |
| AbolerIS Pharma | AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M | Series A | Sep 18, 2023 |  |
| AbolerIS Pharma | AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M | Series A | Sep 18, 2023 |  |
| Minoryx Therapeutics | Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $54.7M | Series C | May 31, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [Columbus Venture Partners](https://shizune.co/investors/profile/columbus-venture-partners) — VC Fund, 2 deals together
- [Investsud](https://shizune.co/investors/profile/investsud) — VC Fund, 2 deals together
- [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital) — VC Fund, 2 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 2 deals together
- [SFPIM](https://shizune.co/investors/profile/sfpim) — VC Fund, 2 deals together
- [Sound Bioventures](https://shizune.co/investors/profile/sound-bioventures) — VC Fund, 2 deals together

## About Criteria Bio Ventures

VC Fund · Barcelona, Spain

Criteria Bio Ventures Life Sciences venture fund backing private biotech companies in Europe and North America with a special focus on Spain and Portugal.

1 contacts available at Criteria Bio Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Pablo Cironi | Managing Director | https://shizune.co/investors/profile/pablo-cironi-8645 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Pablo Cironi invest in?

Pablo Cironi invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pablo Cironi last invest?

The most recent investment recorded for Pablo Cironi closed in Oct 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co